Abstract
Introduction
In recent yea rs peptide receptor radionuclide therapy (PRRT) has utilized synthetic peptides as vectors for radionuclides such as 90 Y and 177 Lu. This has been accomplished with the aid of positron emission tomography (PET), which involves the same vector biomolecules labelled with positron emitters, and was first demonstrated with 68 Ga-labelled somatostatin (SST) analogues for diagnostic imaging of neuroendocrine tumours [1] . Since then growing interest in other positron emitters obtained in generator systems has been observed [2, 3] . The increasing availability of new radionuclides with diagnostic and therapeutic properties offers new possibilities for individualized nuclear medicine options. 44 Sc is a positron emitter radionuclide [Eb+ max = 1475.4 keV, Er = 1157.0 keV (99.9%)] with a half life of 3.97 hours, which can be utilized for diagnostics with 47 Sc as a matched pair for radiotherapy. Additionally, Grignon et al. [4] reported that 44 Sc is an interesting radionuclide for nuclear medicine imaging using b + -g coincidences. The use of 44 Sc with a half-life more than 3 times longer than that of 68 Ga (T ½ = 67.71 min) makes it an useful alternative for diagnostic purposes but also for dosimetry and 47 Sc as radiotherapeutic agents [5] . The availability of 44 Sc is also increasing [3, 6] .
The chemistry of Sc 3+ is similar to that of the lanthanides, and the "lanthanide like" elements. Due to its small ionic radius it is also chemically similar to aluminium and gallium [7] . The thermodynamic stability constant of the 1,4,7,10-teraazacyclododecane-N,N',N',N'''-teraacetic acid (DOTA) complex with Ga 3+ is in the range from 21.3 to 26.1 [8, 9] [7, 8, 11, 12] . All of the above values are similar as indicated from the data reported by Viola-Villegas and Doyle [13] . Hence chelators developed for the complexation of gallium, and the lanthanides can also be used for the complexation of scandium.
Generally, small neuropeptides, such as somatostatin (SST) and gastrin releasing peptide (GRP)/bombesin (BN) analogues, labelled with g -and/or b --emitting radionuclides are investigated for their ability to bind to receptors which are overexpressed in a variety of malignant tumours [14] [15] [16] . The affinity of the designed chelator-peptide construct to these receptors may vary depending on the metal incorporated into the complex [17] . Ga revealed differences in the in vitro and in vivo behaviour of these complexes, which could be attributed to the influence of metal on the complex receptor affinity [18, 19] octreotide (DOTA-TATE), which is a clinically used somatostatin analogue [20, 21] . 
Material and methods

Chemicals
High pressure liquid chromatography (HPLC)
The HPLC system for the quality control of the cold complexes was equipped with UV-VIS detector. The analysis was performed using a reverse phase C-18 Luna column (Phenomenex, USA).
The mobile phase was a gradient of 0.1% TFA (Trifluoroacetic Acid)/H 2 O (Solvent A) and 0.1% TFA/Acetonitrile (ACN) (Solvent B). The elution scheme of solvent B was 0% for 2 min, increased to 40% from 2 to 9 min, remaining at 40% until 15 min, and then decreased to 0% in 3 min from 18 min to 23 remaining at 0%, at a flow rate of 0.6 ml/min.
Cold complexes of DOTA-TATE with nat
Sc and nat
Ga
The cold metal complexes of DOTA-TATE were synthesized and identified according to the previously described method [18] .
Briefly, 100 μg of DOTA-TATE was dissolved in 250 μl ammonium acetate 0.4 M, pH 5, or 250 μl of ascorbic acid (100 mg/ml) was added. An appropriate amount of nat ScCl 3 or nat GaCl 3 solution (1 mg/ml in 0.05 M HCl) was added to obtain a molar ratio of DOTA-TATE to metal 1:5. The sample was incubated at 95°C for 25 minutes and left to cool down to room temperature. The cold complexes were analyzed by HPLC. The samples were purified from free metal by Solid Phase Extraction (SPE) using pre-conditioned C-18 columns (100 mg resin, Sep-Pak, Waters), and the mobile phase consisted of 5 ml of ethanol and 5 ml of 0.9% NaCl. The samples were loaded on the cartridge followed by 5 ml 0.9% NaCl (to elute non-bound In vitro studies
Cell culture
The rat pancreatic cancer cell line AR42J expressing somatostatin receptors subtype 2 (sstr2) was used for the in vitro experiments. The cell line was cultured in RPMI-1640 (Gibco Invitrogen) supplemented with 10% foetal calf serum (Gibco Invitrogen), antibiotics (streptomycin, 100 μg/ml; penicillin, 100 U/ml; Sigma 
Competitive binding studies
The in vitro receptor binding affinity and specificity of value (inhibitory concentration, 50%).
Statistical methods
The results were analyzed by non-linear regression analysis using GraphPad Prism (version TM, GraphPad software, San Diego California, USA). Ga-DOTA-BN[2-14]NH 2 , revealed differences in the in vitro receptor affinity of these analogues (see Table 1 ) [18, 19] . These differences may be attributed to the structural changes in the radioligand molecule, which influence the interaction with the receptor. The introduction of a certain metal or its replacement by another one may provoke considerable alterations in the in vivo binding affinity of a peptide to cell receptors and may have an important impact on the in vivo biodistribution of these radiopharmaceuticals.
Results
Cold
So far, there is no published data on 44 Sc-labelled peptides as PET tracer candidates in terms of in vitro and in vivo behaviour. Therefore, the main goal of this study was to evaluate the influence of the new radionuclide, 44 Sc, on the receptor affinity of another DOTA derivatized peptide which is already well established, such as the somatostatin analogue DOTA-TATE [20, 21] . The 68 Ga-DOTA-TATE was used in direct comparison since 68 Ga complexes with DOTA chelated somatostatin analogues have been showing improved affinity to somatostatin receptor subtypes [17] . Considering the rather short half-life of 68 Ga, the 44 Sc with 3.97 h half-life can be an interesting alternative for conjugation with biomolecules of longer metabolic half-life to allow late PET imaging.
Summary
In the present study [18] ; **Koumarianou et al. [19] 
